REXADEV
DEAD

Serial Number

87146623

Owner

AMGEN INC.

Attorney

Timothy J. Gaul

Filing Date

Aug 22, 2016

Add to watchlist:

No watchlists yet
View on USPTO

REXADEV Trademark

Serial Number: 87146623

REXADEV is a trademark filed by AMGEN INC. on August 22, 2016. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

AMGEN INC. (820 trademarks)

THOUSAND OAKS, CA 91320

Entity Type: 03

Trademark Details

Filing Date

August 22, 2016

Registration Date

Not Registered

Published for Opposition

June 6, 2017

Goods & Services

pharmaceutical preparations, biosimilars and pharmaceutical substances used for the treatment of bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, blood cells, blood vessel, and blood diseases and disorders; pharmaceutical preparations, biosimilars and pharmaceutical substances for the treatment of autoimmune, immune system, inflammatory, inflammatory bowel, gastrointestinal, genitourinary, musculoskeletal, dermatological, pulmonary, respiratory, oncological, hepatological, lymphomas, leukemias, ophthalmic, transplant rejection, cardiovascular, endocrine, neurological, sleep, muscular, and psychiatric diseases and disorders; pharmaceutical preparations and biosimilars, namely, pharmaceutical preparations and pharmaceutical substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, polymyalgia rheumatic, spondyloarthropathies, acute disc prolapse, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Intestinal Behçet's Disease, chronic pouchitis, small bowel lesions, Hermansky-Pudlak syndrome, autoimmune pancreatitis, multiple myeloma, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, chronic inflammatory demyelinating polyneuropathy, autoimmune anemia, autoimmune hemolytic anemia, pure red cell aplasia, idiopathic thrombocytopenic purpura, Evans syndrome, type 1 diabetes mellitus, Sjogren's syndrome, encephalitis, IgG4-related disease, Devic's disease, myositis, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, palmoplantar psoriasis, hidradenitis suppurativa, bullous skin disorder, pemphigus, pemphigoid, kawasaki disease, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, age-related macular degeneration, refractory diabetic macular edema, uveitis, childhood uveitis, uveitic macular edema, choroidal neovascularization, Graves' ophthalmopathy, pyoderma gangrenosum, giant cell arteritis, Netherton syndrome, anaplastic thyroid cancer, breast cancer, ovarian cancer, cervical cancer, gastric cancer, colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, head and neck cancer, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, lymphocyte predominant subtype of Hodgkin's Lymphoma, vasculitis, granulomatosis with polyangiitis, microscopic polyangiitis, graft-versus-host disease, graft-versus-host disease following allogenic hematopoietic stem cell transplantation, graft-versus-host disease following keratoprosthesis, kidney transplant, asthma, chronic fatigue syndrome, major depression, and bipolar depression

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Sep 8, 2020 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Sep 7, 2020 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 23, 2019 EXRA
SOU EXTENSION 5 GRANTED
Nov 22, 2019 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 22, 2019 AITU
SOU EXTENSION 5 FILED
Nov 20, 2019 EXT5
SOU TEAS EXTENSION RECEIVED
Nov 20, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 28, 2019 EXRA
SOU EXTENSION 4 GRANTED
May 24, 2019 EX4G
SOU EXTENSION 4 FILED
May 24, 2019 EXT4
SOU TEAS EXTENSION RECEIVED
May 24, 2019 EEXT
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 7, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 7, 2019 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 24, 2019 EXRA
SOU EXTENSION 3 GRANTED
Jan 22, 2019 EX3G
SOU EXTENSION 3 FILED
Jan 22, 2019 EXT3
SOU TEAS EXTENSION RECEIVED
Jan 22, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 14, 2018 EXRA
SOU EXTENSION 2 GRANTED
Jul 12, 2018 EX2G
SOU EXTENSION 2 FILED
Jul 12, 2018 EXT2
SOU TEAS EXTENSION RECEIVED
Jul 12, 2018 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 27, 2018 EXRA
SOU EXTENSION 1 GRANTED
Jan 25, 2018 EX1G
SOU EXTENSION 1 FILED
Jan 25, 2018 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 25, 2018 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 1, 2017 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 6, 2017 NPUB
PUBLISHED FOR OPPOSITION
Jun 6, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 17, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 26, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 25, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 24, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 24, 2017 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 24, 2017 TCCA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 31, 2016 GNRN
NON-FINAL ACTION E-MAILED
Oct 31, 2016 GNRT
NON-FINAL ACTION WRITTEN
Oct 31, 2016 CNRT
ASSIGNED TO EXAMINER
Oct 28, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 25, 2016 NWOS
NEW APPLICATION ENTERED
Aug 25, 2016 NWAP